📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
8 articles
AVG GRADE
HIGH
score: 0.56
SENTIMENT
BULLISH
TOTAL VIEWS
27
TLX Stock Analysis & AI Grade: HIGH
8 articles analyzed · Sentiment: BULLISH · AI-powered equity research
RECENT COVERAGE · 8 ARTICLES
Telix to Host R&D Day in New York City on September 22, 2026
Telix Pharmaceuticals announced a Research and Development Day scheduled for September 22, 2026, in New York City. This is a standard...
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
Telix Pharmaceuticals (TLX) is attracting analyst attention with a median price target suggesting potential upside of approximately 86%,...
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
Telix Pharmaceuticals announced peer-reviewed publication of its ProstACT SELECT Phase 1 study results in the journal Cancers,...
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix Pharmaceuticals reported Q2 2026 revenue of US$247 million, representing 7% sequential growth and 21% year-over-year expansion,...
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
Telix Pharmaceuticals (TLX) announced first-patient dosing in LUTEON1, a Phase 3 trial for TLX250-Tx in relapsed/recurrent clear cell...
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Telix Pharmaceuticals has completed patient enrollment for its Phase 3 registration study of TLX591-Px (Illuccix®) in Japan, a pivotal...
Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
Telix Pharmaceuticals (TLX) inaugurated its first integrated radiopharmaceutical facility in Melbourne, representing a significant...
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
Telix Pharmaceuticals (TLX) has initiated patient enrollment in the OPTIMAL-e clinical trial, marking a significant expansion of its...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice